Home › Urothelial (Transitional Cell) Carcinoma › South Carolina › Myrtle Beach
Urothelial (Transitional Cell) Carcinoma clinical trials in Myrtle Beach, SC
5 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Myrtle Beach (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #9, Myrtle Beach
A Study of GEN1106 in Participants With Solid Tumors
RecruitingPhase 1
- Carolina Urologic Research Center, Myrtle Beach
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RecruitingPhase 3
- Carolina Urologic Research Center, LLC, Myrtle Beach
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RecruitingPhase 3
- Research Site, Myrtle Beach
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
RecruitingPhase 2
- Site 02-006 - Carolina Urologic Research Center, Myrtle Beach
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
Other studies in Myrtle Beach
- Prostate Cancer24 studies
- Bladder Cancer10 studies
- Non-Muscle Invasive Bladder Cancer9 studies
- Kidney Cancer (Renal Cell Carcinoma)6 studies
- Metastatic Cancer5 studies
- Type 2 Diabetes3 studies
- Castration-Resistant Prostatic Cancer3 studies
- Cancer (all types)3 studies
- Carcinoma in Situ3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.